[
  {
    "ts": "2026-02-23T13:04:00+00:00",
    "headline": "Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer",
    "summary": "Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 BEERSE, BELGIUM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an extension of the RYBREVANT®▼ (amivantamab) marke",
    "url": "https://finance.yahoo.com/news/subcutaneous-rybrevant-amivantamab-approved-european-130400927.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "8e9634e1-8bd1-38d3-99aa-4508191b32f9",
      "content": {
        "id": "8e9634e1-8bd1-38d3-99aa-4508191b32f9",
        "contentType": "STORY",
        "title": "Subcutaneous RYBREVANT®▼ (amivantamab) approved by European Commission for every-three-week and every-four-week dosing for patients with advanced EGFR-mutated non-small cell lung cancer",
        "description": "",
        "summary": "Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all previously approved IV indications, offering fewer administration-related reactions and new dosing options1,2,3,4,5,6 BEERSE, BELGIUM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) has approved an extension of the RYBREVANT®▼ (amivantamab) marke",
        "pubDate": "2026-02-23T13:04:00Z",
        "displayTime": "2026-02-23T13:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3",
          "originalWidth": 2690,
          "originalHeight": 510,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jFgHjEGtPkqKstjJ7xH84w--~B/aD01MTA7dz0yNjkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 2690,
              "height": 510,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/m.9C60wTcxkvOQOLX1h8uw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e0d8c22e436cbd568cb1316cb5beb4b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/subcutaneous-rybrevant-amivantamab-approved-european-130400927.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/subcutaneous-rybrevant-amivantamab-approved-european-130400927.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T12:00:00+00:00",
    "headline": "Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia",
    "summary": "CAMBRIDGE, Mass., February 23, 2026--Blackstone Life Sciences (\"BXLS\") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (\"AML\"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types.",
    "url": "https://finance.yahoo.com/news/blackstone-life-sciences-announces-co-120000684.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3ce00049-e712-3afb-bf7f-73b66c540d39",
      "content": {
        "id": "3ce00049-e712-3afb-bf7f-73b66c540d39",
        "contentType": "STORY",
        "title": "Blackstone Life Sciences Announces a Co-Funding Agreement for Acute Myeloid Leukemia",
        "description": "",
        "summary": "CAMBRIDGE, Mass., February 23, 2026--Blackstone Life Sciences (\"BXLS\") today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor, for acute myeloid leukemia (\"AML\"). AML is the most common type of acute leukemia in adults, yet continues to be extremely challenging to treat, with the lowest survival of all leukemia types.",
        "pubDate": "2026-02-23T12:00:00Z",
        "displayTime": "2026-02-23T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/4e0f92f9f1be137647745a988c258cfa",
          "originalWidth": 1651,
          "originalHeight": 646,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qzK6W3y3294Z9uOP76VnWQ--~B/aD02NDY7dz0xNjUxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4e0f92f9f1be137647745a988c258cfa.cf.webp",
              "width": 1651,
              "height": 646,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g5nC8Ub2YNiw_oqt9qfprA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4e0f92f9f1be137647745a988c258cfa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/blackstone-life-sciences-announces-co-120000684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/blackstone-life-sciences-announces-co-120000684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:46:08+00:00",
    "headline": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-trump-tariffs-novo-stock/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f65a060d-3459-3bd1-ba64-70ed322cb17d",
      "content": {
        "id": "f65a060d-3459-3bd1-ba64-70ed322cb17d",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Falls On New Trump Tariffs; Novo Plunges On Drug Trial Results (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index dropped Monday on higher Trump tariffs. Novo stock plunged on weight-loss drug trial results.",
        "pubDate": "2026-02-23T13:46:08Z",
        "displayTime": "2026-02-23T13:46:08Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f65a060d-3459-3bd1-ba64-70ed322cb17d/stock-market-today-dow-falls.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/95690600b5ffa388417bc5422e1bd05e",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NtJVppLb1ihUxFpSdY7qCg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/95690600b5ffa388417bc5422e1bd05e.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R3CWo1O2o1QmOITxDfYPLg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/95690600b5ffa388417bc5422e1bd05e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-trump-tariffs-novo-stock/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "AAPL"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "QQQ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:44:18+00:00",
    "headline": "Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J",
    "summary": "Gilead Sciences announced an agreement to acquire Arcellx for $115 in cash per share, a 79% premium to the biotech's Friday close.  Gilead will pay an additional $5 per share if sales of its top drug, anito-cell, total at least $6 billion through 2029, which implies strong competition for Johnson & Johnson.  ACLX stock vaulted higher in early Monday stock market action, while GILD dipped slightly.",
    "url": "https://www.investors.com/news/technology/gilead-sciences-anito-cel-arcellx-acquisition/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f57525e3-6a37-3c5e-bc63-85b5f7fdaa11",
      "content": {
        "id": "f57525e3-6a37-3c5e-bc63-85b5f7fdaa11",
        "contentType": "STORY",
        "title": "Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J",
        "description": "",
        "summary": "Gilead Sciences announced an agreement to acquire Arcellx for $115 in cash per share, a 79% premium to the biotech's Friday close.  Gilead will pay an additional $5 per share if sales of its top drug, anito-cell, total at least $6 billion through 2029, which implies strong competition for Johnson & Johnson.  ACLX stock vaulted higher in early Monday stock market action, while GILD dipped slightly.",
        "pubDate": "2026-02-23T13:44:18Z",
        "displayTime": "2026-02-23T13:44:18Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f57525e3-6a37-3c5e-bc63-85b5f7fdaa11/gilead-bets-big-on-new-drug.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d",
          "originalWidth": 945,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3HS_v1sTXYEP8DTCYUYLJg--~B/aD01MzM7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d.cf.webp",
              "width": 945,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I5EJ4LrwA0DL6x_L77OdSA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/220b994ba82b273562061a4d57daf68d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gilead-sciences-anito-cel-arcellx-acquisition/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "LGND"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T13:13:00+00:00",
    "headline": "Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs",
    "summary": "JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-vs-abbvie-growth-131300265.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e7550c84-00ed-39f9-8dff-94d44d403848",
      "content": {
        "id": "e7550c84-00ed-39f9-8dff-94d44d403848",
        "contentType": "STORY",
        "title": "Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs",
        "description": "",
        "summary": "JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.",
        "pubDate": "2026-02-23T13:13:00Z",
        "displayTime": "2026-02-23T13:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rR6iZHXu8FRY2qc4ebuBNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TXlDKOevAW4cJAnlMECSwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-vs-abbvie-growth-131300265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-vs-abbvie-growth-131300265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T15:28:00+00:00",
    "headline": "Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
    "summary": "WHIPPANY, N.J., February 23, 2026--Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
    "url": "https://finance.yahoo.com/news/bayer-alleges-j-j-claims-152800015.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "5d2b0bd9-f0e9-3b90-92bf-b7cdc13a4333",
      "content": {
        "id": "5d2b0bd9-f0e9-3b90-92bf-b7cdc13a4333",
        "contentType": "STORY",
        "title": "Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
        "description": "",
        "summary": "WHIPPANY, N.J., February 23, 2026--Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA",
        "pubDate": "2026-02-23T15:28:00Z",
        "displayTime": "2026-02-23T15:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/19df6d198891cbf4ee3a0178366338df",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u7RsYUNRVvhV8DP_lnXrMA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/19df6d198891cbf4ee3a0178366338df.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tqKGoYq2V4uBiJn34FAJig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/19df6d198891cbf4ee3a0178366338df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayer-alleges-j-j-claims-152800015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayer-alleges-j-j-claims-152800015.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "BAYZF"
            },
            {
              "symbol": "BAYN.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T14:07:00+00:00",
    "headline": "What's in Store for These 5 Medical Companies This Earnings Season?",
    "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
    "url": "https://finance.yahoo.com/news/whats-store-5-medical-companies-140700168.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "09a74d47-a925-34c0-b330-7c1d11c1f4cd",
      "content": {
        "id": "09a74d47-a925-34c0-b330-7c1d11c1f4cd",
        "contentType": "STORY",
        "title": "What's in Store for These 5 Medical Companies This Earnings Season?",
        "description": "",
        "summary": "IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.",
        "pubDate": "2026-02-23T14:07:00Z",
        "displayTime": "2026-02-23T14:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rR6iZHXu8FRY2qc4ebuBNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TXlDKOevAW4cJAnlMECSwQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3ecb7b8f4826ee26a884371aa5efe958.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/whats-store-5-medical-companies-140700168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/whats-store-5-medical-companies-140700168.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RXRX"
            },
            {
              "symbol": "IRWD"
            },
            {
              "symbol": "NTLA"
            },
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T16:09:44+00:00",
    "headline": "Bayer sues Johnson & Johnson over marketing of prostate cancer drug",
    "summary": "NEW YORK, Feb 23 () - Bayer sued Johnson & Johnson ‌on Monday, accusing ‌the rival drugmaker of falsely advertising ​a drug intended to treat prostate cancer. According to a complaint filed in Manhattan ‌federal court, ⁠Johnson & Johnson launched a false advertising campaign against ⁠Bayer's Nubeqa drug, in order to promote and ​demonstrate the ​alleged ​superiority of its ‌own drug, Erleada.",
    "url": "https://finance.yahoo.com/news/bayer-sues-johnson-johnson-over-160944023.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "3ff2588b-3df2-31b4-9936-a2faaea86b4a",
      "content": {
        "id": "3ff2588b-3df2-31b4-9936-a2faaea86b4a",
        "contentType": "STORY",
        "title": "Bayer sues Johnson & Johnson over marketing of prostate cancer drug",
        "description": "",
        "summary": "NEW YORK, Feb 23 () - Bayer sued Johnson & Johnson ‌on Monday, accusing ‌the rival drugmaker of falsely advertising ​a drug intended to treat prostate cancer. According to a complaint filed in Manhattan ‌federal court, ⁠Johnson & Johnson launched a false advertising campaign against ⁠Bayer's Nubeqa drug, in order to promote and ​demonstrate the ​alleged ​superiority of its ‌own drug, Erleada.",
        "pubDate": "2026-02-23T16:09:44Z",
        "displayTime": "2026-02-23T16:09:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/05263b9a7c3d3e92f44c54f8ca9dbb32",
          "originalWidth": 800,
          "originalHeight": 507,
          "caption": "The 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park \"Chempark\" of the chemical industry in Leverkusen, Germany, September 23, 2023. REUTERS/Wolfgang Rattay",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qLv.bBJwTNA_HhsZPw9xXQ--~B/aD01MDc7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/05263b9a7c3d3e92f44c54f8ca9dbb32.cf.webp",
              "width": 800,
              "height": 507,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vX3SwxS3ttNpVRpcH_YF7A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/05263b9a7c3d3e92f44c54f8ca9dbb32.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayer-sues-johnson-johnson-over-160944023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayer-sues-johnson-johnson-over-160944023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:13:39+00:00",
    "headline": "A Look At Johnson & Johnson (JNJ) Valuation After New Long Term TREMFYA Ulcerative Colitis Data",
    "summary": "Johnson & Johnson (JNJ) is in focus after releasing long term QUASAR study data showing TREMFYA sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. See our latest analysis for Johnson & Johnson. Despite a 1 day share price return of 1.79% decline to US$242.49 and some recent legal and competitive headlines, investors have still seen a 90 day share price return of 17.69% and a 1 year total shareholder return...",
    "url": "https://finance.yahoo.com/news/look-johnson-johnson-jnj-valuation-181339738.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d48dd48a-96c0-3c82-9ff7-bb9a0a925835",
      "content": {
        "id": "d48dd48a-96c0-3c82-9ff7-bb9a0a925835",
        "contentType": "STORY",
        "title": "A Look At Johnson & Johnson (JNJ) Valuation After New Long Term TREMFYA Ulcerative Colitis Data",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) is in focus after releasing long term QUASAR study data showing TREMFYA sustained clinical, endoscopic, and histologic outcomes through Week 140 in adults with moderately to severely active ulcerative colitis. See our latest analysis for Johnson & Johnson. Despite a 1 day share price return of 1.79% decline to US$242.49 and some recent legal and competitive headlines, investors have still seen a 90 day share price return of 17.69% and a 1 year total shareholder return...",
        "pubDate": "2026-02-23T18:13:39Z",
        "displayTime": "2026-02-23T18:13:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-johnson-johnson-jnj-valuation-181339738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-johnson-johnson-jnj-valuation-181339738.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T18:11:51+00:00",
    "headline": "Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)",
    "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Bloomberg reported that Johnson & Johnson (NYSE:JNJ) is exploring a possible sale of its orthopedics unit, DePuy Synthes, as part of its broader separation plan. According to people familiar with the matter, several large buyout […]",
    "url": "https://finance.yahoo.com/news/bloomberg-reports-potential-major-asset-181151996.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "05442423-353d-33a6-889a-7e5fcd9b74b3",
      "content": {
        "id": "05442423-353d-33a6-889a-7e5fcd9b74b3",
        "contentType": "STORY",
        "title": "Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Low Volatility Dividend Stocks to Invest in. On February 20, Bloomberg reported that Johnson & Johnson (NYSE:JNJ) is exploring a possible sale of its orthopedics unit, DePuy Synthes, as part of its broader separation plan. According to people familiar with the matter, several large buyout […]",
        "pubDate": "2026-02-23T18:11:51Z",
        "displayTime": "2026-02-23T18:11:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/733e01b2866533a5c5a5725bc85fc155",
          "originalWidth": 8256,
          "originalHeight": 5504,
          "caption": "Bloomberg Reports Potential Major Asset Sale by Johnson & Johnson (JNJ)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tubHqI1qVCPiNF1x9yO6Ww--~B/aD01NTA0O3c9ODI1NjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/733e01b2866533a5c5a5725bc85fc155.cf.webp",
              "width": 8256,
              "height": 5504,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PBiJ1XxEJEk_nDh.eNN0Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/733e01b2866533a5c5a5725bc85fc155.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bloomberg-reports-potential-major-asset-181151996.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bloomberg-reports-potential-major-asset-181151996.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]